Archive | April, 2013

PPMI Bioanalytics Core PI presented at the International Conference on Alpha-Synuclein in Dubai, UAE

Dr. Trojanowski, PI of the PPMI Bioanalytics Core presented on early Synuclein analyses that have been done in PPMI during the Biomarkers session at the International Conference on Alpha-Syunclein in Parkinson?s Disease on March 3, 2013 at 9:45 AM in Dubai. For more information on this presentation, please visit our new Presentations section of the website.

Continue reading...

PPMI focus on LRRK2 gene profiled in two South Florida newspapers

Earlier this month, two Florida newspapers reported on the prevalence of LRRK2 genetic mutations in the Ashkenazi Jewish population and the need for them to receive genetic testing and participate in PPMI. Dr. Stuart Isaacson, director of PPMI site Parkinson?s Disease and Movement Disorders Center of Boca Raton, was interviewed.

Continue reading...

Biospecimen Review Committee Evaluating Requests for PPMI Samples

PPMI?s Biospecimen Review Committee (BRC) convenes every other month to review requests to use available specimens being housed at Corriell, which serves as the PPMI biorepository. To date, 23 requests have been made for use of the biospecimens. Two of those requests have been accepted and fulfilled.

Continue reading...

PPMI launches new prodromal cohort

PPMI has launched a new study arm to enroll and follow a prodromal PD cohort with the goal of providing researchers with the opportunity to examine biomarker progression prior to the onset of motor symptoms. This new cohort seeks to enroll subjects without Parkinson?s disease who have at least one of the following characteristics: hyposmia, REM sleep behavior disorder, LRRK2 genetic mutation.

Continue reading...

PPMI Recruitment Finishes, Complete Cohort Baseline Analysis Coming Soon

PPMI has now finished recruiting the 400 de novo PD and 200 control subjects the study originally set out to identify. This is an important milestone for the study and for those wishing to take advantage of its growing dataset. Already, more than 54,000 downloads have been made from scientists in 37 countries across the globe. In the coming months, the PPMI Steering Committee plans to present at various meetings and publish a paper that will reference the baseline data as a description of the 600+ participants enrolled in PPMI.

Continue reading...

Select Preliminary Baseline Data for 90% of Cohort Recruited is Presented at AAN

PPMI senior leadership presented PPMI data collected so far at the American Academy of Neurology?s 75th annual meeting. The poster used baseline data to give a preliminary sense of the characteristics of the PPMI cohort. The poster also highlights CSF acquisition success rates in PPMI and data from baseline DaTSCANs.

Continue reading...

PPMI Ancillary Studies in Full Swing

An update on the integration of SWEDD's, TAP-PD, fMRI, tracking MCI and dementia, and inclusion of exercise assessment as ancillary studies in PPMI

Continue reading...

PPMI Biospecimens Keep Rolling In: An Inventory of the 2,755 Samples Collected to Date

See the actual numbers of samples of CSF, urine, RNA, serum and plasma that have been collected in PPMI to date.

Continue reading...